FindTrial
Sign In

An open label, parallel group, multicenter study, evaluating the safety and imaging characteristics of florbetapir (18F) in healthy volunteers, patients with mild cognitive impairment (MCI) and patients with Alzheimers disease (AD)

An open label, parallel group, multicenter study, evaluating the safety and imaging characteristics of florbetapir (18F) in healthy volunteers, patients with mild cognitive impairment (MCI) and patients with Alzheimers disease (AD)

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221935
Enrollment
45
Registered
2012-10-10
Start date
2012-10-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Japanese Healthy Volunteers, MCI and AD

Interventions

investigational material(s) Generic name etc : florbetapir (18F) (AV-45) INN of investigational material : Therapeutic category code : 43- Radioactive medicines Dosage and Administration for Investig

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Japanese males or females at least 50 years of age.

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026